Showing 3931-3940 of 6035 results for "".
- PulseSight Therapeutics to Present New Data on Iron Dysregulation and Ferroptosis in AMD at Euretina 2025https://modernod.com/news/pulsesight-therapeutics-to-present-new-data-on-iron-dysregulation-and-ferroptosis-in-amd-at-euretina-2025/2484133/PulseSight Therapeutics announced that its Chief Scientific Officer, Thierry Bordet, PhD, will present new clinical and preclinical findings on the role of iron dysregulation and ferroptosis in age-related macular degeneration (AMD) at the 25th Euretina Congre
- European Commission Approves Mynzepli as a Biosimilar to Eyleahttps://modernod.com/news/european-commission-approves-mynzepli-as-a-biosimilar-to-eylea/2484127/The European Commission has granted marketing authorization for Mynzepli (aflibercept), a biosimilar to Eylea, developed by Alvotech in partnership with Advanz Pharma. The centralized authorization applies t
- Prevent Blindness Forms New Diabetes + the Eyes Advisory Committeehttps://modernod.com/news/prevent-blindness-forms-new-diabetes-the-eyes-advisory-committee/2482934/Prevent Blindness has created a new Diabetes + the Eyes Advisory Committee. The volunteer panel will guide national initiatives to raise awareness, expand access to care, and improve early detection of diabetes-related eye diseases.
- Ocular Therapeutix Secures FDA Special Protocol Assessment for NPDR Trial of Axpaxlihttps://modernod.com/news/ocular-therapeutix-secures-fda-special-protocol-assessment-for-npdr-trial-of-axpaxli/2482930/Ocular Therapeutix has received written agreement from the FDA under a Special Protocol Assessment (SPA) for the registrational trial design of Axpaxli (OTX-TKI) for the treatment of nonproliferative diabetic retinopathy (NPDR).
- New Research Highlights Lumenis Dynamic Muscle Stimulation Technology in Managing Lower Lid Laxity and Blinking Qualityhttps://modernod.com/news/new-research-highlights-lumenis-dynamic-muscle-stimulation-technology-in-managing-lower-lid-laxity-and-blinking-quality/2482929/New findings demonstrating Lumenis’s Dynamic Muscle Stimulation technology (DMSt) can effectively address lower lid laxity and improve blinking quality in patients with dry eye disease (DED).[1]. According to Lumenis,
- PolyActiva Initiates US Phase 2b Clinical Trial of PA5108 Biodegradable Ocular Implant for Glaucoma and OHThttps://modernod.com/news/polyactiva-enrolls-first-patient-in-us-phase-2b-clinical-trial-of-its-ocular-micro-implant-for-glaucoma-and-ocular-hypertension/2482925/PolyActiva announced the enrollment of the first US patient in its phase 2b clinical trial evaluating PA5108, a novel intracameral, biodegradable micro implant designed to provide sustained IOP reduction in patients with primary open-angle glaucoma (POAG)
- New Study Links Physical Activity to Slower Glaucoma Progressionhttps://modernod.com/news/new-study-links-physical-activity-to-slower-glaucoma-progression/2482921/A new study has revealed that higher levels of physical activity may significantly slow the progression of visual field loss in individuals with glaucoma. The findings suggest that lifestyle modifications could become an important complement to traditional glaucoma
- Market Scope: Investor Interest in Ophthalmology Remains Stronghttps://modernod.com/news/market-scope-investor-interest-in-ophthalmology-remains-strong/2482919/The ophthalmic industry continues to command the attention of investors with $620 million raised across 13 transactions in Q2 2025, according to Market Scope’s latest Ophthalmic Deals Report. However, the investment dollars are down from Q2-2024 and
- Kowa Initiates Phase 3 Safety Trial for Glaucoma Drug Candidate NCX 470 in Japanhttps://modernod.com/news/kowa-initiates-phase-3-safety-trial-for-glaucoma-drug-candidate-ncx-470-in-japan/2482918/Nicox announced that its exclusive Japanese partner, Kowa, has officially initiated a phase 3 safety clinical trial for NCX 470 (also referred to as K-911) in Japan. NCX 470 is Nicox’s lead clinical candidate, currently undergoing phase 3 clinical evaluations
- Genentech Unveils 5-Year Data for Susvimo: Long-Term Efficacy and Durability in Wet AMD Treatmenthttps://modernod.com/news/genentech-unveils-five-year-data-for-susvimo-long-term-efficacy-and-durability-in-wet-amd-treatment/2482915/Genentech announced new 5-year data from the phase 3 Portal study, which the company says reaffirms the long-term efficacy, safety, and durability of Susvimo (ranibizumab injection) in treating wet age-related macular degeneration (AMD). The fin